CA3025401A1 - Compositions and methods for treating pulmonary vascular disease - Google Patents
Compositions and methods for treating pulmonary vascular disease Download PDFInfo
- Publication number
- CA3025401A1 CA3025401A1 CA3025401A CA3025401A CA3025401A1 CA 3025401 A1 CA3025401 A1 CA 3025401A1 CA 3025401 A CA3025401 A CA 3025401A CA 3025401 A CA3025401 A CA 3025401A CA 3025401 A1 CA3025401 A1 CA 3025401A1
- Authority
- CA
- Canada
- Prior art keywords
- yap
- gls1
- taz
- pulmonary
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341848P | 2016-05-26 | 2016-05-26 | |
| US62/341,848 | 2016-05-26 | ||
| PCT/US2017/034420 WO2017205595A1 (en) | 2016-05-26 | 2017-05-25 | Compositions and methods for treating pulmonary vascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3025401A1 true CA3025401A1 (en) | 2017-11-30 |
Family
ID=60412630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3025401A Pending CA3025401A1 (en) | 2016-05-26 | 2017-05-25 | Compositions and methods for treating pulmonary vascular disease |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10925869B2 (enExample) |
| EP (2) | EP3970720B1 (enExample) |
| JP (2) | JP7079937B2 (enExample) |
| KR (2) | KR20220120711A (enExample) |
| CN (2) | CN115192719B (enExample) |
| AU (1) | AU2017270092B2 (enExample) |
| CA (1) | CA3025401A1 (enExample) |
| WO (1) | WO2017205595A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017270092B2 (en) * | 2016-05-26 | 2022-04-14 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating pulmonary vascular disease |
| JP7394463B2 (ja) * | 2017-11-22 | 2023-12-08 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｙａｐ１／ｗｗｒｔ１阻害組成物およびｇｌｓ１阻害組成物を投与するための組成物および方法 |
| JP7156856B2 (ja) * | 2018-08-21 | 2022-10-19 | 国立大学法人富山大学 | 抗肥満剤 |
| EP3690110B1 (en) | 2019-02-01 | 2021-06-02 | LG Electronics Inc. | Laundry treating apparatus |
| EP3690109B1 (en) | 2019-02-01 | 2021-05-05 | LG Electronics Inc. | Laundry treating apparatus |
| EP3690108B1 (en) | 2019-02-01 | 2021-05-12 | LG Electronics Inc. | Laundry treating apparatus |
| WO2020226919A1 (en) * | 2019-05-05 | 2020-11-12 | Georgetown University | Use of inhibitors of yap/taz for the treatment of cancer |
| EP3980072A4 (en) * | 2019-06-05 | 2023-06-14 | University of Georgia Research Foundation | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED PULMONARY HYPERTENSION |
| JP7514508B2 (ja) * | 2020-05-19 | 2024-07-11 | 国立大学法人鳥取大学 | 胆道がん治療薬 |
| US20240082158A1 (en) * | 2020-05-21 | 2024-03-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition |
| CN116421591A (zh) * | 2023-05-10 | 2023-07-14 | 哈尔滨医科大学大庆分校 | Ldha抑制剂在制备治疗肺动脉高压的药物中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5798345A (en) | 1990-09-21 | 1998-08-25 | Bone Care International, Inc. | Method of inhibiting the hyperproliferation of malignant cells |
| US5707608A (en) | 1995-08-02 | 1998-01-13 | Qlt Phototherapeutics, Inc. | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
| US5756541A (en) | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US20050119330A1 (en) * | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| US7943179B2 (en) | 2003-09-23 | 2011-05-17 | Massachusetts Institute Of Technology | pH triggerable polymeric particles |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| US20090202540A1 (en) * | 2008-02-11 | 2009-08-13 | Auspex Pharmaceuticals, Inc. | Substituted oxazaphosphorines |
| EP2279267A4 (en) | 2008-03-27 | 2012-01-18 | Vascular Biosciences Inc | METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES |
| KR100963435B1 (ko) | 2008-06-19 | 2010-06-17 | 한국과학기술연구원 | 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법 |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| WO2015138902A1 (en) | 2014-03-14 | 2015-09-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| US20170226507A1 (en) * | 2014-05-05 | 2017-08-10 | The Brigham And Women's Hospital, Inc. | Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases |
| US20160058759A1 (en) * | 2014-07-03 | 2016-03-03 | Board Of Regents, The University Of Texas System | Glutaminase inhibitor therapy |
| WO2016007647A1 (en) | 2014-07-09 | 2016-01-14 | The Johns Hopkins University | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy |
| JP6955443B2 (ja) * | 2014-08-01 | 2021-10-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 肺動脈性肺高血圧症の処置に関する方法および組成物 |
| US10245254B2 (en) | 2014-10-03 | 2019-04-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Glutaminase inhibitors |
| US10517844B2 (en) | 2014-11-13 | 2019-12-31 | Buck Institute For Research On Aging | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications |
| US11491139B2 (en) | 2015-02-12 | 2022-11-08 | The Johns Hopkins University | Inhibition of YAP for breaking tumor immune tolerance |
| US20180311353A1 (en) | 2015-07-02 | 2018-11-01 | Children's Medical Center Corporation | Triplet-triplet annihilation-based upconversion |
| WO2017095751A1 (en) | 2015-12-02 | 2017-06-08 | Partikula Llc | Compositions and methods for modulating cancer cell metabolism |
| AU2017270092B2 (en) | 2016-05-26 | 2022-04-14 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating pulmonary vascular disease |
| JP7394463B2 (ja) * | 2017-11-22 | 2023-12-08 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｙａｐ１／ｗｗｒｔ１阻害組成物およびｇｌｓ１阻害組成物を投与するための組成物および方法 |
-
2017
- 2017-05-25 AU AU2017270092A patent/AU2017270092B2/en active Active
- 2017-05-25 CN CN202210549523.6A patent/CN115192719B/zh active Active
- 2017-05-25 CN CN201780044719.7A patent/CN109843378B/zh active Active
- 2017-05-25 KR KR1020227028385A patent/KR20220120711A/ko not_active Ceased
- 2017-05-25 CA CA3025401A patent/CA3025401A1/en active Pending
- 2017-05-25 JP JP2018561938A patent/JP7079937B2/ja active Active
- 2017-05-25 EP EP21205602.2A patent/EP3970720B1/en active Active
- 2017-05-25 WO PCT/US2017/034420 patent/WO2017205595A1/en not_active Ceased
- 2017-05-25 EP EP17803564.8A patent/EP3463574B1/en active Active
- 2017-05-25 KR KR1020187037697A patent/KR102434879B1/ko active Active
- 2017-05-25 US US16/303,369 patent/US10925869B2/en active Active
-
2021
- 2021-01-14 US US17/148,701 patent/US11672795B2/en active Active
-
2022
- 2022-05-16 JP JP2022079875A patent/JP7411967B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022119825A (ja) | 2022-08-17 |
| CN109843378B (zh) | 2022-06-10 |
| CN109843378A (zh) | 2019-06-04 |
| JP7079937B2 (ja) | 2022-06-03 |
| US11672795B2 (en) | 2023-06-13 |
| CN115192719A (zh) | 2022-10-18 |
| AU2017270092A1 (en) | 2018-12-06 |
| EP3970720B1 (en) | 2023-07-05 |
| US20210154187A1 (en) | 2021-05-27 |
| US10925869B2 (en) | 2021-02-23 |
| WO2017205595A1 (en) | 2017-11-30 |
| AU2017270092B2 (en) | 2022-04-14 |
| KR20220120711A (ko) | 2022-08-30 |
| US20190298710A1 (en) | 2019-10-03 |
| EP3463574B1 (en) | 2021-11-03 |
| CN115192719B (zh) | 2024-03-01 |
| JP2019519533A (ja) | 2019-07-11 |
| KR20190013926A (ko) | 2019-02-11 |
| EP3970720A1 (en) | 2022-03-23 |
| EP3463574A4 (en) | 2020-07-29 |
| JP7411967B2 (ja) | 2024-01-12 |
| KR102434879B1 (ko) | 2022-08-22 |
| EP3463574A1 (en) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11672795B2 (en) | Compositions and methods for treating pulmonary vascular disease | |
| Yang et al. | The ER-localized Ca2+-binding protein calreticulin couples ER stress to autophagy by associating with microtubule-associated protein 1A/1B light chain 3 | |
| Koshman et al. | Regulation of connective tissue growth factor gene expression and fibrosis in human heart failure | |
| US20200155484A1 (en) | Niclosamide for the treatment of cancer metastasis | |
| RU2736499C1 (ru) | Специфические ингибиторы гексокиназы-2 для применения при остром повреждении центральной нервной системы | |
| Kong et al. | Deficiency of the transcriptional regulator p8 results in increased autophagy and apoptosis, and causes impaired heart function | |
| Wu et al. | Recombinant adiponectin peptide promotes neuronal survival after intracerebral haemorrhage by suppressing mitochondrial and ATF4‐CHOP apoptosis pathways in diabetic mice via Smad3 signalling inhibition | |
| Wei et al. | Fibroblast-to-cardiomyocyte lactate shuttle modulates hypertensive cardiac remodelling | |
| Usui et al. | Endogenous muscle atrophy F-box is involved in the development of cardiac rupture after myocardial infarction | |
| Huang et al. | Crosstalk between PML and p53 in response to TGF-β1: A new mechanism of cardiac fibroblast activation | |
| Zeng et al. | LncRNA PART1 attenuates myocardial ischemia-reperfusion injury by regulating TFAP2C/DUSP5 axis via miR-302a-3p | |
| AU2022203624A1 (en) | Compositions and methods for treating pulmonary vascular disease | |
| HK40006997B (en) | Compositions and methods for treating pulmonary vascular disease | |
| Zhang et al. | YBX1-driven TUBB6 upregulation facilitates ocular angiogenesis via WNT3A-FZD8 pathway | |
| Liu et al. | Expression of basigin in the early phase of acute myocardial ischemia in rats | |
| CN110623970A (zh) | 柴胡皂苷b2在制备预防或治疗肾纤维化药物中的应用 | |
| US20250333482A1 (en) | Modulators of mesothelial ecm movement | |
| Liu et al. | TLR9-HIF-1α-VEGF axis is essential for HMGB1-mediate post-myocardial infarction tissue repair | |
| US20160186181A1 (en) | Composition for reducing senescence of cell or subject comprising smurf2 inhibitor and use thereof | |
| Li et al. | BRG1 Ablation in Vascular Smooth Muscle Cells Ameliorates Abdominal Aortic Aneurysm: Mechanism and Translational Potential | |
| JP2017009381A (ja) | 癌の検査方法、癌細胞増殖阻害剤、抗癌剤及び抗癌剤のスクリーニング方法 | |
| HK1241730B (zh) | 治疗癌症干细胞的组合物 | |
| JP2019019119A (ja) | Ｒａｇｅアプタマーを含む癌を治療するための医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220513 |
|
| EEER | Examination request |
Effective date: 20220513 |
|
| EEER | Examination request |
Effective date: 20220513 |
|
| EEER | Examination request |
Effective date: 20220513 |
|
| EEER | Examination request |
Effective date: 20220513 |
|
| EEER | Examination request |
Effective date: 20220513 |